Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 12/20 | 0.52 |
| ▸ | NEK2 | P51955 | 2/20 | 0.52 |
| ▸ | AURKA | O14965 | 2/20 | 0.52 |
| ▸ | CSF1R | P07333 | 2/20 | 0.52 |
| ▸ | RET | P07949 | 2/20 | 0.52 |
| ▸ | KDR | P35968 | 4/20 | 0.49 |
| ▸ | FGFR3 | P22607 | 5/20 | 0.49 |
| ▸ | KIT | P10721 | 1/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13407720 | 0.81 | KDR (0.53) | KDRFGFR3 | |
| SCHEMBL3581745 | 0.80 | KDR (0.61) | FLT3KDRFGFR3KIT | |
| SCHEMBL3323556 | 0.78 | FGFR3 (0.73) | KDRFGFR3 | |
| SCHEMBL31386904 | 0.78 | FLT3 (0.78) | FLT3NEK2AURKACSF1RRET | |
| SCHEMBL3025424 | 0.77 | FLT3 (0.59) | FLT3NEK2AURKACSF1RRET | |
| SCHEMBL3586444 | 0.76 | FGFR3 (0.54) | FLT3NEK2AURKACSF1RRET | |
| SCHEMBL13336773 | 0.75 | FGFR3 (0.80) | KDRFGFR3 | |
| SCHEMBL29615575 | 0.74 | KIT (0.81) | FLT3CSF1RKIT | |
| Formic Acid SCHEMBL3324466 | 0.73 | FGFR3 (0.77) | KDRFGFR3 | |
| SCHEMBL14142549 | 0.73 | FGFR3 (0.41) | KDRFGFR3KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121687-B1 | TRICYCLIC AMINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2015-10-14 | — | — | EP | claimed |
| EP-2121687-B1 | TRICYCLIC AMINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2015-10-14 | — | — | EP | disclosed |
| EP-2121687-B1 | TRICYCLIC AMINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2015-10-14 | — | — | EP | disclosed |
| US-8513276-B2 | Imidazo[1,2-a]pyridine compounds for use in treating cancer | ASTEX THERAPEUTICS LIMITED (GB) | 2013-08-20 | — | — | US | disclosed |
| US-8513276-B2 | Imidazo[1,2-a]pyridine compounds for use in treating cancer | ASTEX THERAPEUTICS LIMITED (GB) | 2013-08-20 | — | — | US | disclosed |
| US-8513276-B2 | Imidazo[1,2-a]pyridine compounds for use in treating cancer | ASTEX THERAPEUTICS LIMITED (GB) | 2013-08-20 | — | — | US | disclosed |
| US-20100093718-A1 | Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-20100093718-A1 | Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-20100093718-A1 | Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093718-A1 | Compounds | FGFR1, FGFR2, PDGFRB | FLT3 16/4885NEK2 1677/4885AURKA 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.